Mark Lotter, founder and CEO of Nuance Biotech, explains why he decided to return to the China market to establish Nuance Biotech, two years after his retirement. He also shares the rationale behind their three-track business model, their exciting portfolio of products, and their ambitions to expand into the Asia-Pacific region, as well as highlights their mission to bring innovative compounds into the market to meet the needs of patients in China.
While the Chinese pharma landscape has developed very rapidly over the past few years, we still see a split within the industry between very commercial-based and very R&D-based companies, with very little movement or synergies between the two groups
